Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Der nächste Perpetua? Warum NevGolds neueste Bohrergebnisse den Vergleich mit dem Milliardenwert PPTA nähren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QDGN | ISIN: US74065P1012 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:53
1,020 US-Dollar
+4,27 % +0,042
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PRELUDE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PRELUDE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PRELUDE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.05.Prelude Therapeutics Inc - 10-Q, Quarterly Report1
06.05.Prelude Therapeutics Inc - 8-K, Current Report1
29.04.JMP maintains $4 target on Prelude Therapeutics stock2
25.04.Prelude Therapeutics Inc - 8-K, Current Report2
25.04.Prelude Therapeutics, Incorporated: Prelude Announces Presentations at 2025 AACR Annual Meeting1
PRELUDE THERAPEUTICS Aktie jetzt für 0€ handeln
28.03.Prelude Therapeutics Inc - 8-K, Current Report2
27.03.Prelude Therapeutics-Aktie steigt nach Insiderkäufen2
27.03.Prelude Therapeutics stock surges on insider buying1
12.03.JMP maintains $4 target on Prelude Therapeutics stock1
10.03.Prelude Therapeutics GAAP EPS of $1.684
10.03.Prelude Therapeutics Inc - S-8, Securities to be offered to employees in employee benefit plans-
10.03.Prelude Therapeutics Inc - 10-K, Annual Report2
10.03.Prelude Therapeutics Inc - 8-K, Current Report2
10.03.Prelude Therapeutics, Incorporated: Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 202592PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung...
► Artikel lesen
11.12.24Prelude Therapeutics, Incorporated: Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid ...137• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future development...
► Artikel lesen
11.12.24Prelude Therapeutics Inc - 8-K, Current Report-
13.09.24Prelude Therapeutics, Incorporated: Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial164- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy...
► Artikel lesen
12.08.24Prelude Therapeutics, Incorporated: Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update204Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1